MedTrace Logo

Pharmacokinetics of SSRI/SNRI After Bariatric Surgery

NCT04928937 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 63

Last updated 2021-06-16

No results posted yet for this study

Summary

Psychiatric disorders and treatment with antidepressants SSRI/SNRI (selective serotonin reuptake inhibitors/ serotonin-norepinephrine reuptake inhibitors) are common in people with morbid obesity who are candidates for bariatric surgery. Although longitudinal assessments reveal positive effects of bariatric surgery on quality of life and mood, depressive disorders may also deteriorate after bariatric surgery. There is few and inconsistent data about the postoperative pharmacokinetics of SSRI/SNRI. The aims of our study were to provide comprehensive data about the postoperative bioavailability of SSRI/SNRI, and the clinical effects on the course of depression.

Conditions

Interventions

PROCEDURE

Roux-en-Y gastric bypass, sleeve gastrectomy

bariatric surgery with the goal loosing weight

Sponsors & Collaborators

  • University Hospital, Zürich

    collaborator OTHER

  • Insel Gruppe AG, University Hospital Bern

    collaborator OTHER

  • Luzerner Kantonsspital

    lead OTHER

Principal Investigators

  • Patrick Pasi, MD · Universitätsspital Zürich

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2020-01-31
Completion
2020-01-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04928937 on ClinicalTrials.gov